PLEASANTON, CALIF., NANJING, CHINA, February 22, 2021-- IASO Biotherapeutics (IASO Bio) and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for CT103A, an investigational chimeric antigen receptor (CAR)-T cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326), for treatment of relapsed/refractory multiple myeloma. NMPA grants Breakthrough Therapy Designation to new medicines that are intended to treat serious conditions and where clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. The BTD designation for CT103A is based on the results observed in ongoing Phase 1/2 study for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) being conducted in China (ChiCTR1800018137).
2020 Nanjing International Life & Health Conference was successfully held in Nanjing International Expo Center during December 9 to 11. The conference was guided by Nanjing Municipal Government and hosted by Nanjing Jiangbei New Area. As one of the most significant sub-forum of the conference, the "Cell Therapy Summit Forum" organized by IASO BIO was successfully held on December 10. The forum has attracted a number of experts, scholars, industry pioneers and on-site audiences to attend and proved participants a lively exchange of forward looking ideas and the sharing of "opportunities & challenges faced by tumor immunotherapy".
IASO Bio, a clinical-stage company focused on developing and commercializing novel cellular immunotherapy to treat cancer, is pleasant to announce the appointment of Dr. Biao Zheng as Chief Scientific Officer (CSO), and the appointment of Dr. Wen Wang as Chief Medical Officer (CMO).
IASO Biotherapeutics recently announced the completion of $60 million in series B financing led by GL Ventures, which is a venture capital fund of Hillhouse Capital focusing on early-stage innovative companies. Biomedicine and medical devices are its key investment areas. This new funding will mainly go toward expanding the company’s product pipeline, promoting the progress of current projects (including regulatory applications and clinical trials in China and the United States), improving the technology of fully human antibody development platform, expanding cooperation with leading international research and development institutions, and accelerating the construction of commercial facilities.
September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received an Investigational New Drug Application (IND) approval from the National Medical Products Administration (NMPA) for the treatment of relapsed refractory multiple myeloma (rr/mm) patients.
IASO Biotherapeutics (IASO Bio),one of the top biotechnology innovators, announced that potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology,the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago Illinois,May 31-June 4[Abstract#8013; Tuesday,June 4,CDT],and the 24th Congress of the European Hematological Society (EHA),June 13–16[Abstract#S827;Saturday,June 15,12:35 PM-12:45 PM CEST].
